Press release
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2017
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2017
Summary
According to the recently published report 'Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2017'; Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR.
The report 'Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2017' outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System and Gastrointestinal which include indications Type 2 Diabetes, Obesity, Alzheimer's Disease, Non-Alcoholic Steatohepatitis (NASH) and Parkinson's Disease.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
To Enquire about this Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41789
Scope
- The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
- The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/gastric-inhibitory-polypeptide-receptor-glucose-dependent-insulinotropic-polypeptide-receptor-or-gipr-pipeline-review-h2-2017
ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.
Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2017 here
News-ID: 791447 • Views: …
More Releases from ReportsWorldwide
World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence…
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports.
Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors.
Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that…
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports.
This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers:
• CommScope/Airvana
• Comba Telecom
• Ericsson
• Huawei Technologies
• Nokia
• SpiderCloud
• ZTE Corporation
This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021.
To view a detailed description and Table of…
More Releases for Polypeptide
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
Polypeptide Market Discern Magnified Growth By 2028
With an increasing number of patients diagnosed with cancer, many pharmaceutical companies are conducting intensive research to discover effective anti-cancer drugs. The World Health Organization (WHO), cancer was the second leading cause of death, killing over 8.8 million people across the globe. 70% patients in low- or middle-income countries, who are diagnosed with cancer succumb to death. It generates needs for an effective oncology medicine that can reduce the number…
Polypeptide Market Analysis , Trends, Opportunity, 2018 to 2028
Global Polypeptides Market: Overview
Polypeptides, the organic polymers containing a large number of amino-acids bonded together on the form of a chain, represent essential portions of proteins with unique pharmacokinetic properties as compared to small molecule drugs and large proteins. Polypeptides play a crucial role in modulating cellular functions and coordinating intercellular communications. There are hardly any other classes of bio-molecules that offer as much chemical diversity as polypeptides do.
Researchers have…
Global Collagen Polypeptide Market Analysis with Forecast to 2025
The Global Collagen Polypeptide Market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025
Scope of the report:
The Global Collagen Polypeptide Market report by Research Cosmos provides a comprehensive analysis of the market including the current trends, growth factors and future forecast. The report also offers deep insights into…
Gastric Inhibitory Polypeptide Receptor-Pipeline Review H2 2017
The report 'Gastric Inhibitory Polypeptide Receptor-Pipeline Review, H2 2017' outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
According to the recently published report 'Gastric Inhibitory Polypeptide Receptor-Pipeline Review, H2 2017'; Gastric Inhibitory Polypeptide Receptor…
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polype …
Market Research Hub (MRH) added a new research report to its vast database titled “Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Pipeline Review, H2 2017” Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1313667
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide…
